Organogenesis Holdings Inc
NASDAQ:ORGO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Organogenesis Holdings Inc
Change in Deffered Taxes
Organogenesis Holdings Inc
Change in Deffered Taxes Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Deffered Taxes | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Organogenesis Holdings Inc
NASDAQ:ORGO
|
Change in Deffered Taxes
$9.5m
|
CAGR 3-Years
69%
|
CAGR 5-Years
144%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Change in Deffered Taxes
-$492m
|
CAGR 3-Years
37%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Change in Deffered Taxes
$160m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Change in Deffered Taxes
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Change in Deffered Taxes
-$510.8m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Change in Deffered Taxes
-$785.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-21%
|
|
Organogenesis Holdings Inc
Glance View
Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 950 full-time employees. The company went IPO on 2016-12-02. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.
See Also
What is Organogenesis Holdings Inc's Change in Deffered Taxes?
Change in Deffered Taxes
9.5m
USD
Based on the financial report for Dec 31, 2025, Organogenesis Holdings Inc's Change in Deffered Taxes amounts to 9.5m USD.
What is Organogenesis Holdings Inc's Change in Deffered Taxes growth rate?
Change in Deffered Taxes CAGR 5Y
144%
The average annual Change in Deffered Taxes growth rates for Organogenesis Holdings Inc have been 69% over the past three years , 144% over the past five years .
